Exelixis, Inc. Announces Fourth Quarter And Full Year 2013 Financial Results

Published: Feb 21, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013.

Q4 2013 Highlights and Recent Events

•Completed enrollment in COMET-1, the phase 3 study of cabozantinib versus prednisone with the primary endpoint of overall survival in patients with advanced metastatic castration-resistant prostate cancer (CRPC).

Help employers find you! Check out all the jobs and post your resume.

Back to news